News & Blogs » Antibody Drug Development News » Developing Bispecific Antibodies

Developing Bispecific Antibodies: Introducing GenScript’s Proprietary SMAB Platform for Therapeutic Antibody Discovery

Developing Bispecific Antibodies

By simultaneously targeting 2 different proteins, Bispecific antibodies are able to reap the benefits of combinatorial therapies without their disadvantages. GenScript’s Proprietary Single Domain Antibody fused to monoclonal antibody (SMAB) is leading the Bispecific revolution, with its novel structure, generation, & functionality. Check out Technology Networks interview with our leading antibody scientists to learn more about this one of a kind platform.

In This Editorial You Will Learn

How Bispecific Antibodies Trigger The Immune System to Fight Against Cancerous Tumors

The Benefits of Using Bispecific Antibodies as Opposed to Monospecific or Combinatorial Therapies

The Innovative Structure and Advanced Functionality of GenScript’s SMAB Platform

In This Editorial You Will Learn
Click HERE To Read The Article in
Technology Networks

Innovative SMAB Bispecific Antibody Discovery Services

Discover the Future of Therapeutic Antibodies

GenScript’s SMAB platform combines the stability of the IgG constant domain with the specificity of both camelid generated nanobodies and naturally generated complementary determining regions. Through our proprietary symmetric design, we can equally bind two completely different antigenic targets with high affinity and developability.

Did You Know That GenScript Has Other Therapeutic Antibody Discovery and Development Services

Antibody Lead Generation

  • Multiple Antigen Choices with Proprietary Sequence and Expression Optimization Technologies
  • Premium Hybridoma Development for High Fusion Efficiency and Superior Affinity
  • Human Naïve Library for Fully Human Therapeutic Antibody Discovery

Antibody Lead Optimization

  • Antibody Humanization & Affinity Maturation Services Using Top-Tier Bioinformatics, Library Generation, Structural Analysis, & Guaranteed Affinity
  • Multi-dimensional Characterization Tools for Multiple In vitro Functional Assays and Biochemical/Biophysical Assays

Subscribe to Receive Updates
& Promotions From GenScript

* We'll never share your email address with a third-party.

Latest News & Blogs

Find More Antibody drug development News
From Bispecific to Trispecific Antibodies in Cancer Immunotherapy

From Bispecific to Trispecific Antibodies in Cancer Immunotherapy

Apr 19, 2021

Biogen's Antibody for Alzheimer's Disease

Biogen's Antibody for Alzheimer's Disease

Dec 07, 2020

Hope for cancer patients: an immune-boosting protein without side effects created

Hope for cancer patients: an immune-boosting protein without side effects created

Jan 22, 2019

As a Gene Cell therapy deliver, mRNA is a more efficient coding language.

As a Gene Cell therapy deliver, mRNA is a more efficient coding language.

Dec 28, 2018

Successful Clinical Results for a Novel CAR-T Cell Therapy: Is the Cure for Advanced Myeloma Patients within Our Reach?

Successful Clinical Results for a Novel CAR-T Cell Therapy: Is the Cure for Advanced Myeloma Patients within Our Reach?

Dec 10, 2018

J&J to Build Blood-Cancer Push With Controversial China Biotech

J&J to Build Blood-Cancer Push With Controversial China Biotech

Dec 04, 2018